TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: odds of poor disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of stay
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: [18F] activity concentration value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine output indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Grade ≥ 3 nonhematologic adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: calculated 10 year CHD risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SCORE mortality
Endpoint domain: Mortality/survival
Primary endpoint: Time to fatigue after the 2-h run
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) changes in total hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bone Mineral Density (BMD) changes in lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean ALT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional improvement as indexed by NIHSS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum resting pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum squeeze pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Discomfort caused by Favre probe
Endpoint domain: Adverse events/effects
Primary endpoint: Hazardous alcohol use prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paced Auditory Serial Addition Test (PASAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multiple Sclerosis Functional Composite (MSFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed-25 Foot Walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of use of insulin delivery device
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Confidence in correct insulin delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New sensitizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mild persistent asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bronchial hyperreactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: recurrence of foot ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Informational support needs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of return to the ED or hospital or death within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Driving simulator performance (SDLP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective sleepiness (MSLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Creativity (RAT score)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Continuously abstinent at 2 months posttreatment
Endpoint domain: Mortality/survival
Primary endpoint: Continuously abstinent at 3 months posttreatment
Endpoint domain: Mortality/survival
Primary endpoint: Asthma morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: range of passive duction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Milk carotenoid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma lutein concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LH secretory patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: anti-HBs persistence (≥10 mIU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: OGTT-stimulated C-peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Post-OGTT glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: breathing resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Italian CGQL score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: virological response to ddl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractures occurring in femoral metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Death due to bleeding
Endpoint domain: Mortality/survival
Primary endpoint: CVD endpoint reduction
Endpoint domain: Mortality/survival
Primary endpoint: losing glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: treatment intensification to maintain HbA1c ≤ 7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: oxLDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: stenosis reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients achieving remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response under treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained response one year after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of procalcitonin for pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of interleukin 6 for pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of CRP for pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality-Adjusted Life Years (QALY)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 2-hour post-load glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rates of polyclonal infections in recurrent malaria cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: eosinophil cell counts in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: levels of FeNO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of asthma symptom-free days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cardiac death incidence
Endpoint domain: Mortality/survival
Primary endpoint: Infarct size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microvascular obstruction extent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to 95% wheal inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to 95% flare inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of nicardipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of nicardipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: re-excision rate for positive margins
Endpoint domain: Adverse events/effects
Primary endpoint: overall costs
Endpoint domain: Resource use
Primary endpoint: Blood urea nitrogen (BUN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: B-Type natriuretic peptide (BNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Control Probability (TCP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Major organ morbidity or mortality
Endpoint domain: Mortality/survival
Primary endpoint: Duration in the intensive care unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term recovery following treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: overall contamination rate
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma serotonin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Colorectal cancer screening adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiorespiratory variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: body composition variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious non-AIDS events
Endpoint domain: Adverse events/effects
Primary endpoint: Mycological cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of burning sensation and buccal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perineal pain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor function recovery (MBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ipsilateral FA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 percent increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Migraine headache intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migraine headache duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Appetite improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in periodontal scores (FMBS and PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Counts of periodontopathogens and salivary mutans streptococci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intermittent claudication distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain reduction measured by visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cecal intubation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: sensitivity of short-segment NCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adverse event-free survival
Endpoint domain: Mortality/survival
Primary endpoint: AF-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Time-to-recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in hopelessness scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Re-presentation with self-harm
Endpoint domain: Adverse events/effects
Primary endpoint: Hospital presentations for non-self-harm reasons
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Fasting C-peptide level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postprandial C-peptide level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ΔC-peptide level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in CS on admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean LVEF (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stroke volume (mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak VO(2) (mL/kg min(‐1))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in weekly alcohol intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite of death, myocardial infarction, or severe, recurrent ischemia at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Mortality of PLC
Endpoint domain: Mortality/survival
Primary endpoint: Response rate at week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rate at week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acceptable bowel cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drowsiness and sedation
Endpoint domain: Adverse events/effects
Primary endpoint: LAA thrombus presence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Long-term problems from normal-looking appendix
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of uncorrected visual acuity >= 0.8 or >= 1.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of haze greater than grade 1
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of abnormal ovaries detected at ultrasonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return rate of first-time blood donors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favorable outcome at 90 days on the extended Glasgow outcome scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Delayed cerebral ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rescue therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: reductions in alcohol craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in cigarette smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular dyssynchrony
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physician-rated nasal symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good or excellent therapeutic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MVS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: motor abilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final height increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height velocity (HV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone age (BA) advancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PDTG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: internal MCBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FMDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma adrenocorticotropic hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Urinary tetrahydrocortisols/tetrahydrocortisone ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Safety and tolerability of UE2343
Endpoint domain: Adverse events/effects
Primary endpoint: Satiety ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Energy intake at lunch
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postoperative symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in cephalometric variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diarrhoea improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication usage reduction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Low birth weight of newborn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: remission rate for dysthymia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission rate for minor depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary Function Recovery (PFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pulmonary Artery Mean Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: amount of remaining biomaterial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-progression survival (P-PS)
Endpoint domain: Mortality/survival
Primary endpoint: Rates of RVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of SVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: impression quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trough FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: TDI scores
Endpoint domain: Life impact
Endpoint subdomain: Dyspnea
Primary endpoint: SGRQ total scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: driving after drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: moderate exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in mammographic density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic floor muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle resistance (endurance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of adverse events involving the eye or the nervous system
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically meaningful changes in ophthalmologic or neurologic test results
Endpoint domain: Adverse events/effects
Primary endpoint: Stimulant abstinence symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum low-density lipoprotein cholesterol (LDL-C) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CAVI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart rate variability (LF and HF power)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in total circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin sensitivity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in triacylglycerol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean grade of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean change in MOS scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Tolerated balloon inflation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recession depth (RD) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in keratinized tissue height (KTH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ERPF (Effective Renal Plasma Flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Glomerular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Endothelial function (reactive hyperemia index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Satisfaction with BAN
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of HLA-DR+ activated lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Force reduction during the 2-min MVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1000-m kayak ergometer performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accumulated 5 × 250-m time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes